A randomized trial of directly administered antiretroviral therapy and adherence case management intervention

被引:76
作者
Wohl, AR
Garland, WH
Valencia, R
Squires, K
Witt, MD
Kovacs, A
Larsen, R
Hader, S
Anthony, MN
Weidle, PJ
机构
[1] Los Angeles Cty Dept Hlth Serv, HIV Epidemiol Program, Los Angeles, CA 90005 USA
[2] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA
[3] Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA
[4] Harbor UCLA Med Ctr, David Geffen Sch Med, Los Angeles Biomed Res Unit, Torrance, CA 90509 USA
[5] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
D O I
10.1086/503906
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. A randomized, controlled trial was conducted to evaluate the impact of a directly administered antiretroviral therapy program (DAART) and intensive adherence case management (IACM) intervention on virologic and immunologic response to highly active antiretroviral therapy (HAART) among patients at 3 public human immunodeficiency virus clinics in Los Angeles County, California. Methods. Participants included 250 treatment-naive and treatment-experienced persons for whom no more than 1 prior HAART regimen had failed. Five days per week for 6 months, a community worker delivered 1 HAART dose to DAART participants and observed the participant take it. IACM participants met weekly with a case manager to overcome barriers to HAART adherence. A control group (the standard of care [SOC] group) received the usual care. Results. The majority of patients were Latino (64%) or African American (24%); 57% were monolingual Spanish speakers. Seventy-five percent of the patients were male, and 64% reported an annual income of <$10,000. In an intent-to-treat analysis, no statistical differences were observed in the percentage of patients with an undetectable viral load (i.e., < 400 copies/mL) at 6 months between the DAART group (54%), IACM group (60%), and SOC group (54%; P > .05). An on-treatment analysis determined that there were no statistical differences in the percentage of patients with an undetectable viral load at 6 months between the DAART group (71%), IACM group (80%), and SOC group (74%; P > .05). Additionally, there were no statistical differences in 6-month changes in the CD4(+) cell count or in self-reported adherence to therapy. Conclusions. Among patients with limited prior HAART experience and adherence barriers that had not been assessed before randomization, no differences were found in virologic or immunologic response for DAART or IACM, compared with SOC, at 6 months. DAART and IACM did not improve short-term outcomes when SOC included other means of adherence support that were not controlled for by the study design.
引用
收藏
页码:1619 / 1627
页数:9
相关论文
共 39 条
  • [1] Brief motivational interviewing to improve adherence to antiretroviral therapy: Development and qualitative pilot assessment of an intervention
    Adamian, MS
    Golin, CE
    Shain, LS
    DeVellis, B
    [J]. AIDS PATIENT CARE AND STDS, 2004, 18 (04) : 229 - 238
  • [2] Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication
    Altice, FL
    Mezger, JA
    Hodges, J
    Bruce, RD
    Marinovich, A
    Walton, M
    Springer, SA
    Friedland, GH
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S376 - S387
  • [3] Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    Bangsberg, DR
    Hecht, FM
    Charlebois, ED
    Zolopa, AR
    Holodniy, M
    Sheiner, L
    Bamberger, JD
    Chesney, MA
    Moss, A
    [J]. AIDS, 2000, 14 (04) : 357 - 366
  • [4] Addressing the challenges of adherence
    Bartlett, JA
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 : S2 - S10
  • [5] The economic viability of antiretroviral adherence interventions
    Bozzette, SA
    Gifford, AL
    [J]. AMERICAN JOURNAL OF MEDICINE, 2003, 115 (08) : 672 - 673
  • [6] Buchanan RJ, 2002, HEALTH CARE FINANC R, V23, P149
  • [7] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
    Carpenter, CCJ
    Cooper, DA
    Fischl, MA
    Gatell, JM
    Gazzard, BG
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schechter, M
    Schooley, RT
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03): : 381 - 390
  • [8] Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
    Casado, JL
    Perez-Elías, MJ
    Antela, A
    Sabido, R
    Martí-Belda, P
    Dronda, F
    Blazquez, J
    Quereda, C
    [J]. AIDS, 1998, 12 (11) : F131 - F135
  • [9] Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments
    Chesney, MA
    Ickovics, JR
    Chambers, DB
    Gifford, AL
    Neidig, J
    Zwickl, B
    Wu, AW
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03): : 255 - 266
  • [10] POPULATION-BASED NORMS FOR THE MINI-MENTAL-STATE-EXAMINATION BY AGE AND EDUCATIONAL-LEVEL
    CRUM, RM
    ANTHONY, JC
    BASSETT, SS
    FOLSTEIN, MF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (18): : 2386 - 2391